Compare CMPS & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPS | OPK |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | 2275 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2011 |
| Metric | CMPS | OPK |
|---|---|---|
| Price | $13.68 | $1.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $25.38 | $1.60 |
| AVG Volume (30 Days) | ★ 3.2M | 2.9M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.35 | $0.98 |
| 52 Week High | $15.40 | $1.61 |
| Indicator | CMPS | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 67.22 |
| Support Level | $5.57 | $1.48 |
| Resistance Level | $14.76 | $1.58 |
| Average True Range (ATR) | 0.96 | 0.06 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 58.12 | 65.97 |
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.